Which don’t get Alzheimer’s. Mice lie, monkeys exaggerate.
That said, this study is cause for cautious optimism. The mechanism they’ve targeted cleared symptoms in 'two of these mouse models: One carried multiple human mutations in amyloid processing; the other carried a human mutation in the tau protein. ’ Mosreso, it does it by modulating NAD+, long a target of interest in AD. From the paper
Nicotinamide adenine dinucleotide (NAD+) homeostasis is central to cellular resilience against oxidative stress, DNA damage, neuroinflammation, blood-brain barrier (BBB) deterioration, impaired hippocampal neurogenesis, synaptic plasticity deficits, and neurodegeneration.
As such it is not only of interest to sufferers of AD but the aging population in general.
MalReynolds@slrpnk.net 3 weeks ago
Which don’t get Alzheimer’s. Mice lie, monkeys exaggerate.
That said, this study is cause for cautious optimism. The mechanism they’ve targeted cleared symptoms in 'two of these mouse models: One carried multiple human mutations in amyloid processing; the other carried a human mutation in the tau protein. ’ Mosreso, it does it by modulating NAD+, long a target of interest in AD. From the paper
As such it is not only of interest to sufferers of AD but the aging population in general.